Donepezil
Treatment for Alzheimers Disease
Typical Dosage: 5-10 mg orally once daily
Effectiveness
45%
Safety Score
60%
Clinical Trials
202
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
5-10 mg orally once daily
Time to Effect
4-6 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
12(Treat 12 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$400
Side Effect Mgmt:$50
Total Annual:$525
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$2,100
Donepezil Outcomes
for Alzheimers Disease
Efficacy Outcomes
Overall Effectiveness
+45%
Response Rate
+25%
Common Side Effects
Nausea
+11%
Diarrhea
+9%
Insomnia
+9%
Muscle cramps
+8%
Vomiting
+6%
Sources:
Active Clinical Trials
2 active trials recruiting for Donepezil in Alzheimers Disease
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)
NCT07768592NOT YET RECRUITINGPHASE1
32 participants
INTERVENTIONAL
Started: Oct 15, 2026
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
NCT07066826RECRUITINGPHASE2, PHASE3
720 participants
INTERVENTIONAL
Beijing, China
Started: Aug 29, 2025
Completed Clinical Trials
17 completed trials for Donepezil in Alzheimers Disease
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
NCT01245530COMPLETEDPHASE3
280 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jun 1, 2008
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
NCT01266525COMPLETEDPHASE2
291 participants
INTERVENTIONAL
Gilbert, United States +81 more
Started: Feb 1, 2011
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
NCT02097056COMPLETEDPHASE4
171 participants
INTERVENTIONAL
Ansan, South Korea +12 more
Started: Feb 1, 2014
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
NCT02064920COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Started: Apr 22, 2014
Neural Correlates In Mild Alzheimer's Disease
NCT00477659COMPLETEDPHASE4
14 participants
INTERVENTIONAL
Milwaukee, United States
Started: Jul 23, 2007
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
NCT02787746COMPLETEDPHASE4
241 participants
INTERVENTIONAL
Beijing, China
Started: Apr 1, 2016
Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg
NCT02550665COMPLETEDPHASE3
176 participants
INTERVENTIONAL
Seoul, South Korea
Started: Dec 1, 2014
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
NCT00478205COMPLETEDPHASE3
1.47K participants
INTERVENTIONAL
Hickory, United States
Started: Jun 1, 2007
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
NCT00566501COMPLETEDPHASE3
915 participants
INTERVENTIONAL
Santa Ana, United States
Started: Dec 14, 2007
A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®
NCT03259958COMPLETEDPHASE1
86 participants
INTERVENTIONAL
Phoenix, United States
Started: Oct 30, 2017
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
NCT01251718COMPLETED
894 participants
OBSERVATIONAL
Anjo, Japan +105 more
Started: Dec 1, 2010
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
NCT02158910COMPLETED
2.23K participants
OBSERVATIONAL
Busan, South Korea +12 more
Started: Mar 1, 2015
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
NCT02162264COMPLETED
8.66K participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Jun 1, 2013
Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease
NCT00408525COMPLETEDPHASE1
41 participants
INTERVENTIONAL
Nashville, United States
Started: Dec 1, 2006
Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia
NCT01023867COMPLETEDNA
88 participants
INTERVENTIONAL
Seoul, South Korea
Started: Mar 1, 2007
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
NCT00381381COMPLETEDPHASE4
199 participants
INTERVENTIONAL
Bundang, South Korea +14 more
Started: May 31, 2006
The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility
NCT00571064COMPLETEDPHASE4
97 participants
INTERVENTIONAL
Birmingham, United States +35 more
Started: Jan 1, 2008
Showing 20 of 205 total trials